SAN DIEGO, June 1, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative drugs firm centered on growing cell therapies that present a purposeful treatment for sufferers with diabetes introduced immediately presentation of a late-breaking ePoster with commentary on behalf of the examine by Manasi Sinha Jaiman, M.D., M.P.H., Vice President, Medical Improvement, on the upcoming American Diabetes Affiliation’s Digital 81st Scientific Sessions to be held on June 25-29, 2021.
The ePoster, “Stem Cell-Derived Islet Alternative Remedy (VC-02) Demonstrates Manufacturing of C-Peptide in Sufferers with Kind 1 Diabetes (T1D) and Hypoglycemia Unawareness” will likely be obtainable for convention attendees to view and submit questions on Friday, June 25, 2021, at 11:30 a.m. ET.
“We imagine that the information introduced at ADA from our stem cell-derived islet alternative remedy program brings us one step nearer to delivering a purposeful treatment for sort 1 diabetes,” stated Dr. Jaiman. “Our mission is to re-define the best way by which diabetes is managed immediately by eliminating the burden of fixed insulin administration with a remedy designed to ship physiological regulation of blood glucose, thus enabling higher well being outcomes for sufferers.”
After the convention, the ePoster will likely be obtainable on the journal Diabetes® web site.
ViaCyte is a privately held regenerative drugs firm growing novel cell alternative therapies based mostly on two main technological advances: cell alternative therapies derived from pluripotent stem cells and medical machine programs for cell encapsulation and implantation. ViaCyte has the chance to make use of these applied sciences to deal with vital human illnesses and issues that may probably be handled by changing misplaced or malfunctioning cells or proteins. The corporate’s first product candidates are being developed as potential long-term remedies for sufferers with sort 1 diabetes to realize glucose management targets and cut back the chance of hypoglycemia and diabetes-related problems. To speed up and broaden the corporate’s efforts, ViaCyte has established collaborative partnerships with main corporations, together with CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. For extra data, please go to www.viacyte.com and join with ViaCyte on Twitter, Fb, and LinkedIn.
About PEC-Direct (VC-02)
ViaCyte’s PEC-Direct (VC-02) product candidate is being developed for therapy of sufferers with sort 1 diabetes who’ve hypoglycemia unawareness and/or excessive glycemic lability. It’s an investigational cell alternative remedy comprised of pancreatic islet progenitor cells in a non-immunoprotective pouch, which permits direct vascularization of the implanted cells. VC-02 is designed to allow manufacturing of each insulin and glucagon to modulate blood glucose, enhance time in vary, and ameliorate or stop problems related to sort 1 diabetes. Part 2 medical research to judge the security and efficacy of VC-02 are ongoing (medical trial identifier: NCT03163511).
In regards to the ADA’s Scientific Periods
The American Diabetes Affiliation’s (ADA) 81st Scientific Periods, the world’s largest scientific assembly centered on diabetes analysis, prevention, and care, will likely be held nearly June 25-29, 2021. Main physicians, scientists, and well being care professionals from all over the world will unveil cutting-edge analysis, therapy suggestions and advances towards a treatment for diabetes. Attendees will obtain unique entry to all digital content material for 90-days after the occasion, with entry ending September 29, 2021. For extra data, go to https://professional.diabetes.org/scientific-sessions.
SOURCE ViaCyte, Inc.